Saline Challenge in Monitoring Asthma Control
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00859274 |
Recruitment Status :
Completed
First Posted : March 11, 2009
Last Update Posted : October 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Asthma | Drug: budesonide | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Saline Challenge in Monitoring Asthma Control |
Study Start Date : | March 2009 |
Actual Primary Completion Date : | October 2013 |
Actual Study Completion Date : | October 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Budesonide
All patients receive this treatment to induce a change in asthma control
|
Drug: budesonide
Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management. |
- Changes in responsiveness to hypertonic saline cough challenge [ Time Frame: Before budesonide treatment, and after 1, 4, and 12 weeks' treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- symptomatic asthma
Exclusion Criteria:
- usage of inhaled or oral corticosteroids
- recent febrile respiratory infection
- severe, unstable asthma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00859274
Finland | |
Department of Respiratory Medicine, Kuopio University Hospital | |
Kuopio, Finland, 70211 |
Responsible Party: | Heikki Koskela, Respiratory Physician, Kuopio University Hospital |
ClinicalTrials.gov Identifier: | NCT00859274 |
Other Study ID Numbers: |
KUH5801112 |
First Posted: | March 11, 2009 Key Record Dates |
Last Update Posted: | October 10, 2013 |
Last Verified: | October 2013 |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Budesonide |
Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |